Paul Joseph Barreira, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Soccer | 4 | 2019 | 120 | 1.260 |
Why?
|
| Employment, Supported | 6 | 2011 | 31 | 1.050 |
Why?
|
| Rehabilitation, Vocational | 3 | 2011 | 85 | 0.670 |
Why?
|
| Mental Disorders | 15 | 2012 | 6423 | 0.540 |
Why?
|
| Community Mental Health Services | 5 | 2010 | 400 | 0.530 |
Why?
|
| Leg Injuries | 1 | 2016 | 187 | 0.510 |
Why?
|
| Athletic Injuries | 3 | 2019 | 1135 | 0.440 |
Why?
|
| Rehabilitation | 1 | 2010 | 134 | 0.360 |
Why?
|
| Desensitization, Immunologic | 1 | 2014 | 490 | 0.350 |
Why?
|
| Mental Health Services | 6 | 2008 | 1608 | 0.340 |
Why?
|
| Ticlopidine | 1 | 2014 | 880 | 0.330 |
Why?
|
| Personal Autonomy | 1 | 2008 | 299 | 0.280 |
Why?
|
| Drug Hypersensitivity | 1 | 2014 | 868 | 0.270 |
Why?
|
| Patient Participation | 3 | 2010 | 1464 | 0.250 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 4980 | 0.230 |
Why?
|
| Community Mental Health Centers | 2 | 2001 | 102 | 0.230 |
Why?
|
| Choice Behavior | 2 | 2008 | 798 | 0.230 |
Why?
|
| Social Support | 1 | 2011 | 2119 | 0.200 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 3004 | 0.200 |
Why?
|
| Mumps virus | 1 | 2020 | 29 | 0.200 |
Why?
|
| Mumps | 1 | 2020 | 66 | 0.190 |
Why?
|
| Contract Services | 1 | 1999 | 99 | 0.180 |
Why?
|
| Certification | 3 | 2006 | 414 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3701 | 0.160 |
Why?
|
| Schizophrenic Psychology | 2 | 2006 | 1683 | 0.160 |
Why?
|
| Jogging | 1 | 2016 | 17 | 0.160 |
Why?
|
| Self-Injurious Behavior | 2 | 2012 | 430 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2010 | 9561 | 0.150 |
Why?
|
| Program Evaluation | 2 | 2010 | 2529 | 0.150 |
Why?
|
| Genome, Viral | 1 | 2020 | 672 | 0.140 |
Why?
|
| Acceleration | 1 | 2016 | 175 | 0.140 |
Why?
|
| Muscle Strength | 1 | 2019 | 567 | 0.140 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 265 | 0.130 |
Why?
|
| Peer Group | 2 | 2011 | 637 | 0.130 |
Why?
|
| Propranolol | 3 | 1984 | 517 | 0.120 |
Why?
|
| Professional-Patient Relations | 2 | 2010 | 727 | 0.120 |
Why?
|
| Motor Skills | 1 | 2016 | 525 | 0.120 |
Why?
|
| Life Expectancy | 1 | 1999 | 1122 | 0.120 |
Why?
|
| Immobilization | 1 | 2014 | 250 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2001 | 7480 | 0.110 |
Why?
|
| Motivation | 2 | 2005 | 1894 | 0.110 |
Why?
|
| Students | 2 | 2012 | 1553 | 0.110 |
Why?
|
| Task Performance and Analysis | 1 | 2016 | 815 | 0.110 |
Why?
|
| Anthropometry | 1 | 2016 | 1379 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2000 | 963 | 0.100 |
Why?
|
| Massachusetts | 6 | 2008 | 8734 | 0.100 |
Why?
|
| Psychotic Disorders | 4 | 2004 | 2826 | 0.100 |
Why?
|
| Insurance, Psychiatric | 1 | 2010 | 68 | 0.100 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 1721 | 0.100 |
Why?
|
| Muscular Atrophy | 1 | 2014 | 353 | 0.100 |
Why?
|
| Alcoholic Intoxication | 1 | 2011 | 183 | 0.090 |
Why?
|
| Adult | 25 | 2019 | 212129 | 0.090 |
Why?
|
| Health Services Research | 2 | 2009 | 1837 | 0.090 |
Why?
|
| Schizophrenia | 4 | 2006 | 6741 | 0.090 |
Why?
|
| Akathisia, Drug-Induced | 3 | 1984 | 68 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2014 | 1235 | 0.080 |
Why?
|
| Substance-Related Disorders | 2 | 2004 | 4189 | 0.080 |
Why?
|
| Psychomotor Agitation | 3 | 1984 | 274 | 0.080 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2010 | 334 | 0.080 |
Why?
|
| Psychiatry | 1 | 1999 | 1615 | 0.080 |
Why?
|
| Male | 27 | 2019 | 351081 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 1485 | 0.080 |
Why?
|
| Medicaid | 2 | 2004 | 2621 | 0.080 |
Why?
|
| Emotions | 1 | 2018 | 2441 | 0.080 |
Why?
|
| Psychotropic Drugs | 1 | 1992 | 904 | 0.080 |
Why?
|
| Humans | 43 | 2020 | 715124 | 0.080 |
Why?
|
| Health Policy | 1 | 1999 | 2622 | 0.070 |
Why?
|
| Models, Organizational | 2 | 2000 | 587 | 0.070 |
Why?
|
| Universities | 1 | 2011 | 885 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2010 | 2935 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 3 | 2001 | 2266 | 0.070 |
Why?
|
| Self-Help Groups | 1 | 2006 | 209 | 0.070 |
Why?
|
| Vertigo | 1 | 2006 | 193 | 0.070 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 1994 | 1570 | 0.070 |
Why?
|
| Random Allocation | 1 | 2009 | 2461 | 0.060 |
Why?
|
| Body Composition | 1 | 2014 | 2398 | 0.060 |
Why?
|
| Thirst | 1 | 1984 | 37 | 0.060 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 1984 | 66 | 0.060 |
Why?
|
| Paranoid Disorders | 1 | 1983 | 55 | 0.060 |
Why?
|
| Suicidal Ideation | 1 | 2012 | 1112 | 0.060 |
Why?
|
| Metoprolol | 1 | 1984 | 90 | 0.060 |
Why?
|
| Employment | 1 | 2010 | 1100 | 0.060 |
Why?
|
| Drinking Behavior | 1 | 1984 | 108 | 0.060 |
Why?
|
| Antidepressive Agents | 2 | 1988 | 2836 | 0.060 |
Why?
|
| Hospitals, Psychiatric | 2 | 2001 | 331 | 0.060 |
Why?
|
| Research Subjects | 1 | 2005 | 246 | 0.060 |
Why?
|
| New York City | 2 | 2007 | 668 | 0.060 |
Why?
|
| Paroxetine | 1 | 2003 | 173 | 0.060 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 713 | 0.060 |
Why?
|
| Exercise | 1 | 2018 | 5319 | 0.050 |
Why?
|
| Assertiveness | 1 | 2001 | 20 | 0.050 |
Why?
|
| Group Homes | 1 | 2001 | 20 | 0.050 |
Why?
|
| Commitment of Mentally Ill | 1 | 2001 | 84 | 0.050 |
Why?
|
| Program Development | 1 | 2008 | 1330 | 0.050 |
Why?
|
| Suicide | 1 | 2012 | 1567 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2008 | 1149 | 0.050 |
Why?
|
| Data Collection | 1 | 2010 | 3293 | 0.050 |
Why?
|
| Dementia | 1 | 1994 | 2254 | 0.050 |
Why?
|
| Bereavement | 1 | 2004 | 256 | 0.050 |
Why?
|
| Health Surveys | 1 | 2011 | 4021 | 0.050 |
Why?
|
| Benchmarking | 2 | 2010 | 928 | 0.050 |
Why?
|
| Antipsychotic Agents | 4 | 1992 | 3067 | 0.050 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2019 | 42 | 0.050 |
Why?
|
| Female | 23 | 2018 | 377334 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2006 | 1141 | 0.040 |
Why?
|
| Fluoxetine | 1 | 2003 | 763 | 0.040 |
Why?
|
| Proprioception | 1 | 2019 | 129 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 19499 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 484 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2006 | 1778 | 0.040 |
Why?
|
| Bipolar Disorder | 5 | 1999 | 5050 | 0.040 |
Why?
|
| Public Health Administration | 1 | 1999 | 236 | 0.040 |
Why?
|
| Cooperative Behavior | 2 | 2007 | 1562 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2018 | 637 | 0.040 |
Why?
|
| Placebos | 1 | 2001 | 1733 | 0.040 |
Why?
|
| United States | 9 | 2020 | 67665 | 0.040 |
Why?
|
| Depressive Disorder | 2 | 1988 | 3817 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 2001 | 800 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2011 | 3748 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2001 | 869 | 0.030 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2003 | 1428 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 15258 | 0.030 |
Why?
|
| Body Fluid Compartments | 1 | 2014 | 51 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 34394 | 0.030 |
Why?
|
| Depressive Disorder, Major | 2 | 2003 | 4465 | 0.030 |
Why?
|
| Life Change Events | 2 | 2012 | 941 | 0.030 |
Why?
|
| Middle Aged | 12 | 2011 | 214871 | 0.030 |
Why?
|
| Teaching | 1 | 2001 | 1189 | 0.030 |
Why?
|
| Phylogeny | 1 | 2020 | 2799 | 0.030 |
Why?
|
| Aged | 6 | 2014 | 162674 | 0.030 |
Why?
|
| Patient Care Team | 2 | 2001 | 2592 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1992 | 402 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2020 | 1975 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2003 | 2059 | 0.030 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2012 | 154 | 0.030 |
Why?
|
| Resistance Training | 1 | 2014 | 151 | 0.030 |
Why?
|
| Solutions | 1 | 1992 | 415 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2014 | 576 | 0.030 |
Why?
|
| Biological Availability | 1 | 1992 | 403 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2005 | 3463 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 1999 | 2509 | 0.030 |
Why?
|
| Length of Stay | 2 | 2001 | 6278 | 0.030 |
Why?
|
| Knee Joint | 1 | 2019 | 1568 | 0.030 |
Why?
|
| Homosexuality | 1 | 2011 | 270 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2012 | 638 | 0.020 |
Why?
|
| Adolescent | 7 | 2019 | 84999 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2004 | 9022 | 0.020 |
Why?
|
| Atrophy | 1 | 1994 | 1506 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 5718 | 0.020 |
Why?
|
| Young Adult | 4 | 2019 | 56155 | 0.020 |
Why?
|
| Severity of Illness Index | 3 | 2006 | 16011 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 39285 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2001 | 2496 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 1994 | 1892 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2014 | 913 | 0.020 |
Why?
|
| Cause of Death | 1 | 1999 | 3587 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2014 | 973 | 0.020 |
Why?
|
| Anger | 1 | 2011 | 405 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 4910 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2012 | 748 | 0.020 |
Why?
|
| Vaccination | 1 | 2020 | 2941 | 0.020 |
Why?
|
| Parkinson Disease, Secondary | 2 | 1984 | 126 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 23283 | 0.020 |
Why?
|
| Lithiasis | 1 | 2006 | 16 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2009 | 426 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2007 | 314 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2011 | 72255 | 0.020 |
Why?
|
| Pilot Projects | 1 | 1999 | 8042 | 0.020 |
Why?
|
| Researcher-Subject Relations | 1 | 2005 | 16 | 0.020 |
Why?
|
| Haloperidol | 2 | 1984 | 396 | 0.020 |
Why?
|
| Genotype | 1 | 2020 | 12921 | 0.020 |
Why?
|
| Amantadine | 1 | 1984 | 56 | 0.020 |
Why?
|
| Thioridazine | 1 | 1984 | 35 | 0.020 |
Why?
|
| Perphenazine | 1 | 1984 | 33 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1992 | 3963 | 0.020 |
Why?
|
| Doxepin | 1 | 1983 | 17 | 0.020 |
Why?
|
| Phenelzine | 1 | 1983 | 32 | 0.020 |
Why?
|
| Imipramine | 1 | 1983 | 104 | 0.020 |
Why?
|
| Vestibular Diseases | 1 | 2006 | 221 | 0.020 |
Why?
|
| Amitriptyline | 1 | 1983 | 114 | 0.020 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1983 | 168 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 1984 | 349 | 0.010 |
Why?
|
| Body Weight | 1 | 2014 | 4692 | 0.010 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2005 | 270 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 1434 | 0.010 |
Why?
|
| Hospitals, State | 1 | 2001 | 30 | 0.010 |
Why?
|
| Mothers | 1 | 2012 | 2013 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 1992 | 2341 | 0.010 |
Why?
|
| Hospitalization | 1 | 2001 | 9718 | 0.010 |
Why?
|
| Licensure, Hospital | 1 | 2001 | 3 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2014 | 3235 | 0.010 |
Why?
|
| Hospitals, Private | 1 | 2001 | 60 | 0.010 |
Why?
|
| Caudate Nucleus | 1 | 2003 | 402 | 0.010 |
Why?
|
| Delusions | 1 | 1983 | 299 | 0.010 |
Why?
|
| Attitude to Death | 1 | 2004 | 378 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 2006 | 817 | 0.010 |
Why?
|
| Hyponatremia | 1 | 1984 | 306 | 0.010 |
Why?
|
| Restless Legs Syndrome | 1 | 1983 | 221 | 0.010 |
Why?
|
| Hospitals, Public | 1 | 2001 | 203 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2007 | 2595 | 0.010 |
Why?
|
| Risk | 1 | 2012 | 9772 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2004 | 743 | 0.010 |
Why?
|
| Respiratory Sounds | 1 | 1984 | 682 | 0.010 |
Why?
|
| Risk Factors | 2 | 2012 | 70704 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2006 | 2299 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 1660 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2006 | 1659 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1984 | 1230 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 1944 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 13573 | 0.010 |
Why?
|
| Sex Factors | 1 | 2011 | 10651 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1983 | 1949 | 0.010 |
Why?
|
| Demography | 1 | 2001 | 1621 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13594 | 0.010 |
Why?
|
| Mutation | 1 | 2020 | 29442 | 0.010 |
Why?
|
| Oxygen | 1 | 2006 | 4169 | 0.010 |
Why?
|
| Neurons | 1 | 1994 | 9419 | 0.010 |
Why?
|
| Acute Disease | 1 | 1984 | 7177 | 0.010 |
Why?
|
| Hippocampus | 1 | 2006 | 3654 | 0.010 |
Why?
|
| Time Factors | 2 | 2006 | 41081 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2001 | 2831 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2006 | 6922 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 3396 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1983 | 2587 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 8016 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10531 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2006 | 3987 | 0.010 |
Why?
|
| Health Status | 1 | 2004 | 4021 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2006 | 6548 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1994 | 20398 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 12404 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 10423 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 3033 | 0.010 |
Why?
|
| Insurance Coverage | 1 | 2001 | 1863 | 0.010 |
Why?
|
| Research Design | 1 | 2005 | 5876 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 11900 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 8912 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 21790 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1984 | 8566 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1983 | 13268 | 0.010 |
Why?
|
| Brain | 1 | 1994 | 25188 | 0.000 |
Why?
|
| Medicare | 1 | 2001 | 5759 | 0.000 |
Why?
|
| Drug Tolerance | 1 | 1984 | 396 | 0.000 |
Why?
|
| Lithium | 1 | 1984 | 615 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1983 | 1737 | 0.000 |
Why?
|